Expert Interview
Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for obesity and various metabolic disorders with an endocrinologist
Ticker(s): VKTXInstitution: Columbia
- Assistant Professor of Medicine in the Division of Endocrinology at Columbia University.
- Manages over 200 patients with obesity and diabetes.
- Research expertise in the area of the central regulation of energy balance and metabolism and in the management of pituitary diseases; clinical practice includes neuroendocrinology, reproductive endocrinology, menopause, and the management of weight and metabolic disorders.
Roughly how patients do you treat with obesity? and have you prescribed Mounjaro (tirzepatide) to any of these patients
Does a dual GLP-1/GIP Receptor Agonist have a clear benefit to you over semaglutide?
What are your thoughts and key take aways from the Phase 1 trial of VK2735?
Added By: sara_adminPlease discuss if there are additional beneficial synergistic merits above and beyond the activity of each individual component.
Added By: userad5df6c5Do you think Viking Therapeutics plans to make an oral version of VK2735 is feasible?
Added By: sara_adminHow would you rate your level of excitement for VK2735 on a scale from 1-10?(10 being the most excited)
Added By: sara_adminIs insurance coverage a big factor in starting patients on a dual GLP-1/GIP Receptor Agonist?
Added By: sara_adminHow do you see the side effect profile? Would there be a differentially higher tolerance of side effects in diabetic patients vs. obese patients. Do you view a lower side effect profile (as suggested by the 2735 P1 data) as a major factor for patient compliance in the diabetic and/or obese patient population?
Added By: malkmusAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
